<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572960</url>
  </required_header>
  <id_info>
    <org_study_id>2014-LSB</org_study_id>
    <nct_id>NCT02572960</nct_id>
  </id_info>
  <brief_title>Physiologic Interactions Between the Adrenal- and the Parathyroid Glands</brief_title>
  <acronym>AldOst</acronym>
  <official_title>Physiologic Interactions Between the Adrenal- and the Parathyroid Glands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate possible physiologic interactions between the adrenal- and the parathyroid
      glands in patients with secondary hyperparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In primary hyperparathyroidism, chronic-elevated PTH levels seem to stimulate the
      renin-angiotensin-aldosterone system (RAAS) which may explain the increased risk of
      cardiovascular disease. In addition to increased PTH levels, vitamin D has been shown to
      inhibit the RAAS. However, a possible physiologic interaction needs further investigation.

      The purpose of the study is to investigate changes in the RAAS in otherwise healthy
      postmenopausal women with secondary hyperparathyroidism due to vitamin D deficiency when
      p-PTH is normalized.

      Furthermore, we will evaluate whether an angiotensin 2 receptor blocker can lower PTH in
      patients with secondary hyperparathyroidism.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aldosterone, before and after 12 weeks of daily cholecalciferol treatment</measure>
    <time_frame>Change from baseline p-aldosterone at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone, before and after, daily ARB administrations</measure>
    <time_frame>Change from baseline p-PTH at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Change from baseline arterial stiffness at 12 weeks</time_frame>
    <description>Spygmocor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours arterial stiffness as measured by tonometry</measure>
    <time_frame>Change from baseline arterial stiffness PWV at 12 weeks</time_frame>
    <description>Arteriograph 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours blood pressure measured by tonometry</measure>
    <time_frame>Change from baseline systolic pressure at 12 weeks</time_frame>
    <description>Arteriograph 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance as measured by stadiometer (Meitur Ltd)</measure>
    <time_frame>Change from postural balance at 12 weeks</time_frame>
    <description>Postural stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength as measured by isometric tests</measure>
    <time_frame>Change from baseline isometric muscle strength at 12 weeks</time_frame>
    <description>Effects on muscle strength (isometric tests of flexion and extension of thigh and hand), two function-tests (timed up-and go and timed stand-and-sit),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density and geometry as measured by QCT scans</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Bone quality in spine and hip as assessed by high resolution quantitative computed tomography HRQCT-scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density and geometry as measured by HRpQCT scans</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Bone quality in ankle and forearm as assessed by high resolution peripheral quantitative computed tomography HRpQCT-scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density by DXA</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Bone density assessed by dual energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Change from baseline at 2, 6 and 12 weeks</time_frame>
    <description>Hearth rhythm, shortened QT interval, hypertrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of calcium- and bone metabolism</measure>
    <time_frame>Change from baseline at 2, 6 and 12 weeks</time_frame>
    <description>Effects of intervention on biochemical markers of calcium and bone metabolism, such as calcium, phosphate, parathyroid hormone, calcitriol, vitamin D-binding protein, bone-specific alkaline phosphatase, osteocalcin, and N-terminal propeptide of type 1 procollagen (P1NP). Also C-terminal telopeptide of type 1 collagen (CTX) and N-telopeptide of type 1 collagen (NTX) among others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, SF36</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>SF36v2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, WHO-5</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>WHO-5 well being index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Physical activity scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperparathyroid symptoms</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Pasieka's parathyroid symptoms score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol and Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>2 weeks of Valsartan 80 mg per day</description>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_label>Cholecalciferol and Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Valsartan</intervention_name>
    <description>2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>12 weeks of daily cholecalciferol treatment, 70 microgram per day</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_label>Cholecalciferol and Valsartan</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo cholecalciferol</intervention_name>
    <description>12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Secondary hyperparathyroidism due to Vitamin D deficiency

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Renal failure

          -  Liver failure

          -  Treatment with antihypertensive medication or diuretics

          -  Treatment with lithium, NSAID or glucocorticoids

          -  Calcium supplement more than 500 mg per day or Vitamin D supplement more than 25
             microgram per day

          -  Medical treatment for osteoporosis

          -  Systolic blood pressure below 120 mmHg

          -  Hypercalcaemia (more than 1,33mmol/L)

          -  Use of solarium or planned trip to countries, that might increase the endogenous
             vitamin D synthesis

          -  Allergic reaction to ACEi or ARBs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Rejnmark, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Internal medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Bislev, MD</last_name>
    <phone>(+45) 78 46 76 81</phone>
    <email>lise.sofie@auh.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Rejnmark, Professor</last_name>
    <phone>(+45) 78 46 76 97</phone>
    <email>larsni@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Bislev, MD</last_name>
      <email>lise.sofie@auh.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Lars Rejnmark, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

